CASMED Names Brian Wagner as Chief Commercial Officer

BRANFORD, Conn., Oct. 2, 2013 (GLOBE NEWSWIRE) -- CAS Medical Systems,
Inc. (Nasdaq:CASM) (CASMED), a leader in medical devices for
non-invasive patient monitoring, today announced it has named Brian J.
Wagner as Chief Commercial Officer, effective immediately. Mr. Wagner
has 20 years of general management, business development, sales, and
marketing experience in the medical product and device industry.

"Brian has the experience and skills to drive the introduction and
ongoing success of our next generation FORE-SIGHT ELITE(TM) Cerebral
Oximetry products and 740 SELECT(TM) vital signs monitors," said Thomas
M. Patton, President and Chief Executive Officer of CASMED. "He has a
proven ability to motivate sales teams, position innovative medical
technologies to gain market share, and manage programs to achieve
strong financial results. Brian is an important addition to the CASMED
team as we plan for accelerated growth."

Most recently, Mr. Wagner was Senior Vice President and Chief Marketing
Officer for Philips Imaging Systems, a $7 billion revenue business,
where he led worldwide marketing across eight operating divisions.
Prior to that he held a series of executive management positions at
Kimberly-Clark Health Care, including General Manager of the Global
Pain and Temperature Management Division and Vice President of Global
Strategic Marketing and Business Development. Also, Mr. Wagner has held
the position of Vice President and General Manager of Rubbermaid
Healthcare, a medical division which he developed and launched,
focusing on electronic medical administrative records. In addition, he
has held various sales and marketing management positions of increasing
responsibility with Guidant Corporation and Boston Scientific during
years of unprecedented growth.

Mr. Wagner earned his Master's in Biology from Harvard University, and
a Bachelor of Science from Miami University of Ohio.

About CASMED(R) -- Monitoring What's Vital

CASMED is a leading developer and manufacturer of medical devices for
non-invasive patient monitoring. The Company's FORE-SIGHT(R) Absolute
Cerebral Oximeter provides a highly accurate, non-invasive, continuous
measurement of absolute cerebral tissue oxygen saturation. Direct
monitoring of tissue oxygenation provides a superior and powerful tool
to alert clinicians to otherwise unrecognized and dangerously low
levels of oxygenation of the brain and other tissues, thereby allowing
them to intervene appropriately in the care of their patients. In
addition to FORE-SIGHT Oximeters and accessories, the Company provides
a line of bedside patient vital signs monitoring products, proprietary
non-invasive blood pressure monitoring solutions for OEM use, neonatal
intensive care supplies, and service. CASMED products are designed to
provide unique monitoring solutions that are vital to patient care. For
more information regarding CASMED, visit the Company's website at
www.casmed.com.

Statements included in this press release, which are not historical in
nature, are forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Statements relating to the future performance of the Company are
subject to many factors including, but not limited to, the customer
acceptance of the products in the market, the introduction of
competitive products and product development, the impact of any product
liability or other adverse litigation, working capital and availability
of capital, commercialization and technological difficulties, the
impact of actions and events involving key customers, vendors, lenders,
competitors, and other risks detailed in the Company's Form 10-K for
the year ended December 31, 2012, and other subsequent Securities and
Exchange Commission filings.

Such statements are based upon the current beliefs and expectations of
the Company's management and are subject to significant risks and
uncertainties. Actual results may differ from those set forth in the
forward-looking statements. When used in this press release, the terms
"anticipate", "believe", "estimate", "expect", "may", "objective",
"plan", "possible", "potential", "project", "will", and similar
expressions identify forward-looking statements. The forward-looking
statements contained in this press release are made as of the date
hereof, and we do not undertake any obligation to update any
forward-looking statements, whether as a result of future events, new
information, or otherwise.

Company ContactCAS Medical Systems, Inc.Jeffery A. BairdChief Financial
Officer(203) [email protected]

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.